UC Davis study: Latino smokers in California on Medi-Cal still not getting help needed to quit

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A team of researchers with the UC Davis Comprehensive Cancer Center found that even with expanded access to Medi-Cal health coverage, Latino smokers in California continue to get less help than non-Latino white people quitting smoking.

Results from a cross-sectional study of 1,861 participants, published in JAMA Network Open, highlighted the inequity. 

The Affordable Care Act increased access to Medicaid, which is called Medi-Cal in California. 

By the fall of 2014, 2.8 million more people in the state gained access to Medi-Cal. Of these, 41% were newly insured non-elderly Latinos. The percentage of smokers covered by Medi-Cal increased substantially, from 19.3% before the ACA to 41.5% afterward.

The research shows that Latino smokers on Medi-Cal do not receive the same amount of tobacco cessation advice and assistance that non-Latino white smokers on Medi-Cal receive when they are seen by health professionals.

The lead author of the study, Cindy Valencia, said using strategies to engage tobacco users outside of a clinical encounter, such as proactive outreach and community-based engagement, may help address this disparity.

The study was conducted as part of Valencia’s PhD dissertation in Public Health Sciences. She is the first graduate of the program and a Latina.

Table of Contents

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more
The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, Pulmonary Pathology Society, Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations for the testing of immunotherapy biomarkers, including programmed cell death ligand-1 and tumor mutation burden in patients with non-small cell lung carcinoma.

Login